Figure 1




Figure 2






Figure 2 (continued)




1= Molecular weight markers, 2= PNT2 lysate, 3= 1542 lysate, 4=DU145 lysate, 5=LnCap lysate

Angus George DALGLEISH et al.
"Human Prostate Cell Lines In Cancer Treatment"
Attorney Docket No.: 37945-0054


Figure 3





Angus George DALGLEISH et al.

"Human Prostate Cell Lines In Cancer Treatment"
Attorney Docket No.: 37945-0054











Figure 3 (continued)












Angus George DALGLEISH et al.
"Human Prostate Cell Lines In Cancer Treatment"
Attorney Docket No.: 37945-0054

Figure 4

Patient 110






Figure 4 (continued)




Figure 5






Figure 6




Figure 7




Figure 8




Figure 9

Patient	Slope Pre treatment	Slope Post treatment	Doubling time (days) Pre- treatment	Doubling time (days) Post treatment	
### 25 EK#* -	0.0038	0.0014			* 5 = 0 0 A
	- W - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1	A TALL A LA TRACK MORE SALES CONTRACT TO SALES C	500 1 100 100 100 100		$\vec{p} = 0.04$
2	0.0065				4 - 4 - 4
3	0.0046	0.0033	152	213	
4	0.0041	0.0032	169	217	
5	0.0043	0.0018	161	37.7	p = 0.08 .
6	0.0021	0.0235	324	29	
7	0.0038	0.0015	184	475	p = 0.1
8	0.0046	0.0053	150	130	
9	0.009	0.0041	77	168	∜p = 0.00 5
10	0.0113	0.0064	61	109	p = 0.009
11	0.003	0.0027	234	261	
12	0.0072	0 .0028	96	248	p = 0.001
13	0.0075	0.0123	92	56	
14	0.0157	0.0024	44	294	>p = 0.004
15	0.0002	0.0033	2999	213	

Figure 10

